Boston Therapeutics Strengthens its Medical Advisory Board

Posted by Samy Goldfarb

September 24, 2014 at 9:55 AM

Boston_Logo_300_dpi_smallBoston Therapeutics, Inc. (BTHE-OTCQB), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, has appointed Meng Hee Tan, M.D. to serve as its Consulting Medical Director and a member of its Medical Advisory Team. Dr. Tan is expected to help guide the Company's development of its diabetes-related treatments.

Dr. Tan is a professor of internal medicine at the University of Michigan and attending physician in metabolism, endocrinology, and diabetes at the University of Michigan Health System. A member of the American Diabetes Association and the American College of Endocrinology, he is the author or coauthor of more than 110 peer-reviewed publications in the area of diabetes and carbohydrate metabolism. He is a past senior medical director of the Diabetes Endocrine Platform Team at Eli Lilly. He received an M.D. from Dalhousie University.

*******************************************
Visit our Corporate Profile and Key Points pages for more
information, including the latest research and headlines,
on Boston Therapeutics, Inc. (BTHE-OTCQB).
*******************************************

Topics: BTHE

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic